Law360, New York (January 23, 2012, 7:24 PM ET) -- Abbott Laboratories sued Zydus Pharmaceuticals (USA) LLC in Delaware federal court Friday, alleging the drugmaker infringed its patent for Niaspan prescription niacin tablets by seeking regulatory approval to make a generic version of the cholesterol drug.
Zydus notified Abbott on Dec. 8 that it had filed an abbreviated new drug application with the U.S. Food and Drug Administration, seeking the right to market generic extended-release niacin tablets equivalent to Niaspan, according to the complaint. Niaspan helps control cholesterol and arterial plaque buildup, according to Abbott marketing...
Abbott Sues Generic Maker Over Cholesterol Drug Patent
To view the full article, take a free trial now.
